DARE

Dare Bioscience Inc

0.9300

-0.4400-32.12%

After Hours: 0.8998 -0.0302 -3.25%19:58 08/14 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1.550/1.370

TODAY RANGE0.7650-1.610

VOL8.09M

MARKET CAP13.93M

52 WEEK RANGE0.7650-3.780

AVG VOL (3M)419.64K

% TURNOVER52.72%

TURNOVER--

P/E (TTM)-0.8946

% RANGE61.68%

EPS(TTM)-1.0396

P/E(FORWARD)-1.0333

P/B18.45

BVPS0.0504

DIVIDEND--

P/S13.08

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP12.67M

SHARES OUTSTANDING14.98M

NEXT EARNINGS11/11-11/16

FREE FLOAT13.62M

LOT SIZE1

EX-DATE07/01/2024

News

Press Releases

Financial Reports

Profile

TipRanks·8h ago
Analysts’ Top Healthcare Picks: Daré Bioscience (DARE), Medicus Pharma Ltd (MDCX)
NASDAQ·1d ago
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates
Seeking Alpha·1d ago
Dare Bioscience GAAP EPS of -$0.20 beats by $0.10, revenue of $187.5M
Dow Jones·1d ago
*Dare Bioscience 2Q Loss/Shr 20c >DARE
Dow Jones·1d ago
Press Release: Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances
Seeking Alpha·1d ago
Here are the major earnings after the close Thursday
NASDAQ·2d ago
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
TipRanks·07/24 13:29
Daré Bioscience Releases New Investor Corporate Presentation
TipRanks·07/17 21:32
Daré Bioscience Faces Nasdaq Listing Compliance Challenges
TipRanks·07/17 16:31
Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors
TipRanks·07/13 17:25
Daré Bioscience Updates Investors With New Presentation
TipRanks·06/22 14:00
Daré Bioscience Issues New Corporate Investor Presentation
TipRanks·06/12 21:42
Daré Bioscience Shareholders Back Governance and Capital Plans
TipRanks·05/26 12:19
Dare Bioscience receives NIH funding award notice to advance DARE-HPV
Dow Jones·05/26 12:00
Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-2.11%

860.19

Biogen Inc

BIIB

-0.39%

207.13

Amgen Inc

AMGN

+0.54%

418.42

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+19.44%

0.1100

Lilly Eli & Co

LLY

-0.74%

Celgene

CELG

0.00%

108.24

Therapeuticsmd Inc

TXMD

+0.48%

2.080

Johnson & Johnson

JNJ

-0.66%

260.35

Abbvie Inc

ABBV

-0.54%

249.46

Zoetis Inc

ZTS

+0.69%

75.35

Gilead Sciences Inc

GILD

+1.67%

138.14

Novo-Nordisk A/S

NVO

+2.81%

47.26

Bristol-Myers Squibb Co

BMY

+0.13%

63.69

Alexion Pharms

ALXN

+1.70%

182.50

PFE

Sanofi FR

SNY

+0.15%

43.63

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-0.01%

152.31

Dr Reddys Labs

RDY

+0.24%

12.42

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.